SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today reported that oral arguments were held before the U.S. Court of Appeals for the Federal Circuit in the appeal of the U.S. District Court for the District of Delaware’s May 2025 decision upholding Acadia’s U.S. Patent No. 11,452,721 (the ‘721 patent), which covers the NUPLAZID® (pimavanserin) 34 mg capsule formulation. “We continue to believe in the strength of our position on the NUPLAZID formulation patent, on which t

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Bayer’s SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Recent Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, in Combination With Antiplatelet Therapy Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved SUNHARBO® (asundexian), 50 mg tablets, a first-in-class, once daily, Factor XIa inhibitor indicat

SAN DIEGO--(BUSINESS WIRE)--Avenzo Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in London

BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the third quarter 2026. Financial Highlights Three Months Ended   (In millions, except per share amounts) October 2,     September 26,     2026     2025   GAAP           Revenue $ 305.0     $ 247.8   Operating Income $ 13.9     $ 21.8   Net Income $ 2.0     $ 10.7   Diluted EPS $ 0.05    

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. Jefferies Global Healthcare Conference in London, UK Fireside chat on Wednesday, November 18 at 3:00 p.m. Greenwich Mean Time Piper Sandler 38th Annual Healthcare Conference in New York, NY Fireside chat on Tuesday, December 1 at 8:00 a.m. Eastern Time Interested parties may access live and archived

EWING, N.J. & ROCHESTER, N.Y.--(BUSINESS WIRE)---- $OLED #OLED--UDC and OLEDWorks announced a collaboration to evaluate cyan OLED lighting for automated driving system (ADS) communication applications.

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the third quarter of 2026.

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading global health and wellness platform, today announced financial results for the third quarter ended September 30, 2026. “In healthcare, whoever owns the customer relationship wins, and that’s exactly what we’re building toward at Hims & Hers. Today, customers want real choice, real value, and a care team that knows them,” said Andrew Dudum, co-founder and CEO. “Everythin

SAN DIEGO, Calif.--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present two data presentations related to Alzheimer's disease psychosis (ADP) and remlifanserin at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) conference, taking place November 16-19, 2026, in Boston. Acadia's presentations include an oral presentation featuring findings from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin in patients

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO)(“Myomo” or the “Company”), a wearable medical robotics platform company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three and nine months ended September 30, 2026. “The focus on our four success pillars helped deliver record revenue and solid operating leverage in the quarter, resulting in breakeven Adjusted EBITDA and se

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced third quarter 2026 financial results and provided a business update. “Q3 2026 marked the beginning of a new trajectory for Hyperfine. We delivered record revenue, gross profit, and gross margin, and for the first time quarterly revenue exceeded net

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. (NASDAQ: PAYS), a provider of patient affordability offerings, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries, today announced financial results for the third quarter 2026. Third Quarter 2026 Financial Highlights Revenues of $30.80 million in Q3’26, up 42.6% from Q3’25 Pharma revenue increased 109.8% to $16.62 million in Q3’26 versus Q3’25; added 62 net patient a

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading global health and wellness platform, announced the appointment of Andrew Huberman, Ph.D., to the company’s Board of Directors. Dr. Huberman is a world-renowned neuroscientist and tenured professor in the Departments of Neurobiology and Ophthalmology at Stanford University School of Medicine. He has authored or co-authored more than 75 peer-reviewed articles in respected scientific journals

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class cancer therapies, today announced financial results for the quarter ended September 30, 2026, and provided a business update. “We made significant progress across our oncology pipeline in recent months,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Immunome. “We continue to advance varegacestat toward approva

NEW YORK--(BUSINESS WIRE)-- #GAD--Definium Therapeutics, Inc. (“Definium” or the “Company”) (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today reported financial results for the quarter ended September 30, 2026, and recent highlights. The Company also reported positive initial results from its Phase 2a trial of DT402 in adults with ASD, with improvements obser

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events:2026 Jefferies Global Healthcare Conference in London – November 16-19, 2026Type: Fireside Chat PresentationDate/Time: November 18, 2026, 11:00 am GMTCiti’s 2026 Global Healthcare Conference – November 30 - December 3, 2026Type: Fireside Chat PresentationDate/Time: December 2, 2026, 2:20 pm ESTPiper Sandler 38th Annual Hea

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of positive results from the company’s Phase 2b clinical trial that evaluated the safety and efficacy of three doses of once-weekly, subcutaneous efinopegdutide (4 mg, 7 mg and 10 mg), an investigational injectable GLP-1/glucagon receptor co-agonist, versus placebo for the treatment of adults with MASH and stage F2 or F3 liver fibrosis. The findings were prese

PHILADELPHIA--(BUSINESS WIRE)--Virion Therapeutics, LLC, a clinical-stage biotechnology company, developing novel T cell-based immunotherapies that utilize checkpoint modifiers, today announced at AASLD’s The Liver Meeting®, in Denver, CO, that an intramuscular prime dose of VRON-0200 alone, its novel, first-in-class, immunotherapy for HBV Functional Cure, induced anti-HBV activity with continued HBsAg declines, without rebound, up to 2+ years post dosing, in all chronically HBV-infected treate

ORLANDO, Fla.--(BUSINESS WIRE)--The American College of Rheumatology (ACR) and the Lupus Foundation of America (LFA) have honored two rheumatologists at Hospital for Special Surgery (HSS) with prestigious career awards recognizing their transformative contributions to lupus research, education and patient care. The ceremonies took place during the ACR Convergence conference in Orlando, Florida, from November 6 to 11. Mary K. Crow, MD, received the Evelyn V. Hess Award from the LFA, which honors

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--CyberKnife inventor John Adler, MD, wins the 2026 Fogarty Prize for frameless, image-guided radiosurgery, transforming care for more than 1M patients

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the American Heart Association (AHA) Scientific Sessions 2026, adding to the robust body of evidence demonstrating the strength of RNAi-powered TTR silencing with AMVUTTRA® (vutrisiran). The analyses, including data from the HELIOS-B Phase 3 two-year open-label extension (OLE) period, show that patients with transthyretin amyloidosis with cardiomyop

EAST PROVIDENCE, R.I.--(BUSINESS WIRE)--The Nordson EFD PICO Pµlse® XP HV jetting system is designed for extremely precise (XP) assembly applications utilizing high-viscosity (HV) materials.

THE WOODLANDS, Texas--(BUSINESS WIRE)--Everleap Fertility, a U.S. leader in fertility care formerly known as RMA Houston, and part of IVI Institute, the global leader in reproductive medicine, announced the opening of Everleap Fertility The Woodlands, a new clinic that provides greater access to care for those living and working in the Northern Houston suburban community. The full-service facility, located at 9303 New Trails Drive, Suite 100, is Everleap Fertility’s second location in Texas. “T

LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced data to be presented at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow). It marks ViiV Healthcare’s largest congress presence of the year, with 39 abstracts covering real-world evidence findings for long-acting injectable medicines, pipeline research and patient perspectives. Jean van Wyk, MBChB, MFPM, Chief Medical Officer

NEWPORT, R.I.--(BUSINESS WIRE)--Project Omega today announced that it has raised $80 million in its Series A financing led by B Capital with participation from noa VC, 645 Ventures, and other leading investors in nuclear technology and national security. The financing will accelerate the company's work to close America's nuclear fuel cycle and transform it into a source for long duration power systems, fuel for nuclear reactors and strategic isotopes for commercial, scientific and medical use.

IRVINE, Calif.--(BUSINESS WIRE)-- #BlackFriday--Hyperice, a global high-performance wellness brand, today announced its annual Black Friday and Holiday sales, offering the deepest savings of the year across its full product suite of Normatec dynamic air compression, Hypervolt percussion massage, Venom thermal, Hyperice X contrast, and vibration recovery technology products. The season opens with the dedicated Nike x Hyperice Hyperboot sale, with 25% off bringing it to a best-ever price of $599 for a limited t

WASHINGTON--(BUSINESS WIRE)-- #FBA--Expanded FC27 programming connects the fiber infrastructure industry with growing opportunities in broadband, AI, and quantum.

PITTSBURGH--(BUSINESS WIRE)-- #AI--Impossible Metals today announced that its Eureka Collection System™ has become the first in the world to selectively recover polymetallic nodules from the deep ocean using a fully autonomous underwater robot, completing a scientific dive in the Clarion-Clipperton Zone at a depth of over 4,000 meters (2.5 miles). It is the first time ever a fully autonomous underwater robot has selectively collected nodules, and done so gently hovering above the seabed without a ris

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior leadership will participate in the following upcoming conferences: A.G.P. Virtual Consumer Showcase Virtual showcase offering consumer company management teams a platform to share their story with the investment community Location: Virtual Date: November 11 - 12, 2026 Format: Fireside chat

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced initial clinical results from the Phase 1 study of JANX011 in healthy volunteers and outlined its planned clinical development strategy in autoimmune diseases. JANX011 is the first program from Janux’s proprietary Adaptive Immune Response Modulator (ARM) platform to enter clinical development. The ARM platfo

PETALUMA, Calif.--(BUSINESS WIRE)---- $QTI #BreastCancer--QT Imaging Holdings, Inc. (Nasdaq: QTI) (“QT Imaging” or the “Company”), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announced that the Centers for Medicare & Medicaid Services (CMS) has established a separately payable Medicare hospital outpatient classification for diagnostic QTscan® examinations, effective January 1, 2027. CMS recognized that QTscan diagnostic s

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company developing and commercializing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Caren Deardorf to its Board of Directors, effective Nov 9, 2026. Ms. Deardorf brings decades of leadership experience across the pharmaceutical and biotechnology industries, with deep expertise in commercial strate

NORTHBROOK, Ill.--(BUSINESS WIRE)--UL Solutions Inc. (NYSE: ULS), a global leader in applied safety science, today announced that senior management of the company will attend the following investor conferences: Baird Global Industrial Conference – Nov. 12 J.P. Morgan Ultimate Services Investor Conference – Nov. 17 - Live webcast at 11:40 a.m. EST Citi Business, Leisure and Transport Conference – Nov. 23 UBS Global Industrials and Transportation Conference – Dec. 1 - Live webcast at 1:00 p.m. ES

ATLANTA--(BUSINESS WIRE)--Mirion (NYSE: MIR) announced today that Chairman and Chief Executive Officer, Thomas Logan, and Chief Financial Officer and Medical Group President, Brian Schopfer, will present at Baird’s 2026 Global Industrial Conference. The presentation will begin at 5:05 PM ET on Tuesday, November 10, 2026. The presentation will be webcast live at Mirion's Investor Relations Page where a webcast link will be displayed under the "Events and Presentations” section. An archive of the

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced presentations by management at the following upcoming investor conferences:Stifel Healthcare Conference 2026 in New York: Fireside Chat on Wednesday, November 11, 2026, at 4:40 p.m. ET.2026 Jefferies Global Healthcare Conference in London: Presentat

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced initial dose-escalation data from its ongoing Phase 1b study of subcutaneous plamotamab, a bispecific CD20 x CD3 T-cell engager, in adults with rheumatoid arthritis. The data are being presented in a poster session at the American College of Rheumatology (ACR) Convergence 2026 conference in

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced financial results for the third quarter ended September 30, 2026. “We delivered higher than expected topline growth in the third quarter, with revenues up 6.3% sequentially, despite continued market softness. This first step in restoring growth reflects sequential improvement across all our businesses. The actions we initiated last quarter to improve commercia

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value healthcare company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience, will participate in fireside chats at the following upcoming investor conferences. Jefferies Global Healthcare Conference in London, UK on Tuesday, November 17; fireside chat at 3:00 pm Greenwich Mean Time 9th Annual Evercore Healt

LONDON & WARREN, N.J.--(BUSINESS WIRE)--Tenpoint Therapeutics, Ltd., a global commercial ophthalmic pharmaceutical company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced its telehealth prescribing program. This program connects eligible adults with blurry close-up vision with a convenient way to be evaluated online by an ophthalmologist or optometrist to determine eligibility for filling a prescription of YUVEZZI™ (carbachol and brimonidine t

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the third quarter ended September 30, 2026. Third Quarter 2026 Financial Results Total revenue of $35.1 million, compared with $20.6 million in the third quarter of 2025 HEPZATO KIT™ revenue of $32.7 million, compared to $19.3 million in the third quarter of 2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the third quarter ended September 30, 2026, and provided corporate updates. “We are executing with discipline as we complete the final steps toward our planned BLA submission for TA-ERT in December, which we believ

SAN DIEGO--(BUSINESS WIRE)--Qureator, a leading techbio company delivering regulatory-grade translational data through its vTIME 3D human tissue platform, presented preclinical data evaluating the dual pharmacology of a PD-1xVEGF bispecific antibody and the vascular safety profile of a T-cell engager in a poster at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting. “Developing effective cancer therapies requires a deeper understanding of how treatments interact with the complex

LOVELAND, Colo.--(BUSINESS WIRE)-- #LoveAntech--Parasites & Vectors study: Antech’s KeyScreen™ GI Parasite PCR found parasites in twice as many samples as antigen testing and flotation combined.

SAN DIEGO--(BUSINESS WIRE)--Inocras Inc., a bioinformatics-led company harnessing the power of whole-genome data and proprietary analytics to deliver curated insights, today announced that it will present the first public results from its multimodal agentic AI framework for automating variant curation and clinical interpretation of cancer whole-genome sequencing (WGS) analysis at the Association for Molecular Pathology (AMP) 2026 Annual Meeting & Expo, taking place November 10–14 in Seattle

ENGLEWOOD, N.J.--(BUSINESS WIRE)--Phase 2/3: CD206-targeted glucocorticoid 101-PGC-005 beat dexamethasone (HR 2.31), no added steroid; ACR 2026 poster data; partners sought

NEWARK, Calif.--(BUSINESS WIRE)--Corsair Pharma Announces Positive Outcome from FDA Pre-IND Meeting for TRX-248 Transdermal System for Pulmonary Arterial Hypertension (PAH)

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced continued global expansion, expanded FDA approval, and financial results for the third quarter ended September 30, 2026. ImmunityBio continued to advance a broad clinical pipeline spanning bladder cancer, non-small cell lung cancer, and hematologic malignancies with expanded FDA approval and global expansion of ANKTIVA in nonmuscle invasive bladder cancer (NMIBC). AN

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the third quarter ended September 30, 2026 and recent business and scientific highlights. “The third quarter was marked by continued execution across our clinical pipeline and meaningful progress in expanding the opportuni

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced third quarter 2026 financial results and highlighted recent corporate updates. “During the third quarter, we continued to execute across all aspects of our NGN-401 program as we advance toward potential commercialization,” said Rachel McMinn, Ph.D., Founder and Chief Executive Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Brixton Biosciences (Brixton), a clinical-stage life sciences company focused on developing a nerve-selective biomaterial designed to provide targeted and durable relief from pain, today announced results from the pivotal NICE clinical trial, which demonstrated that Reneurx™ Nerve-Selective Therapy was superior to intraarticular corticosteroid (IACS) injection for reducing pain in adults with symptomatic knee osteoarthritis. The data were presented by Yogesh Mi

BEDFORD, Mass.--(BUSINESS WIRE)--Delix closes $100M Series C led by strategic pharma and SV Health neurodegen fund to advance the 1st true neuroplastogen analog of psychedelic to PhII

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to ten newly hired non-executive employees consisting of options to purchase an aggregate of 269,800 common shares of the Company (the "Options") with effective grant dates of November 9, 20

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced positive phase 1 results for VRDN-008. “Today's VRDN-008 data exceeded expectations and demonstrates a potentially transformative FcRn-inhibitor profile. Based on these data, we believe VRDN-008 dosed subcutaneously every 8 weeks can deliver deep and sustain

JERUSALEM & CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) (“ImmunityBio”) and Rafa Laboratories Ltd. (TASE: RAFA) (“Rafa”) today announced that the Israeli Ministry of Health (MoH) has granted approval for ANKTIVA® (nogapendekin alfa inbakicept), indicated in combination with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. Th

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that it has received a Not Approvable Letter from the U.S. Food and Drug Administration (FDA) in response to its Premarket Approval (PMA) application for Optune Mya® for the treatment of adult patients with brain metastases from non-small cell lung cancer following stereotactic radiation. The Not Approvable Letter indicates that the FDA determined that uncertainty around the degree of clinical benefit provided by Optune

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced positive topline results from Part B of its randomized, double-blind, placebo-controlled, registration-directed Phase 2/3 clinical trial (Study ‘302’) evaluating VDPHL01, an investigational, proprietary, extended-release oral minoxidil formulation, in over 500 males with mild-

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced topline clinical data from its Phase 2 trial (FTH-PIK-201; NCT06463028; GOG-3111) of PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib, given with paclitaxel to patients with advanced endometrioid endometrial cancer and a PI3K/AKT/mTOR (PAM) pathway mutation who ha

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that its Phase 2 TibuSHIELD study, which evaluated tibulizumab (ZB-106) in adults with moderate-to-severe hidradenitis suppurativa (HS), did not meet its primary endpoint of percentage change from baseline in

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the third quarter ended September 30, 2026. “In 2026, we continue to advance innovative medicines for people with serious diseases, underscored by three approvals for groundbreaking first-in-class medicines, two of which are Ionis-owned,” said Brett P. Monia, Ph.D., chief executive officer of Ionis. “TRYNGOLZA, our first launch in a large in

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update during fireside chat sessions at two upcoming investor conferences in London. UBS Global Biopharma Conference on Monday, November 16, 2026, from 10:00 a.m. to 10:30 a.m., GMT. Jefferies Global Healthcare Conference on Tuesday, November 17, 2026, from 2:00 p.m. to 2:25 p.m

ACTON, Mass.--(BUSINESS WIRE)--In recognition of World Diabetes Day on November 14, 2026, Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its “Give Yourself the Freedom to” campaign designed to raise awareness of the often overlooked emotional and mental demands of living with diabetes and encourage people living with diabetes to prioritize their own well-being. “Living with d

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it has separated the company's CRHX-101 (formerly SPR-202) program into Adrenyx Biosciences, Inc. ("Adrenyx"), a newly formed wholly-owned subsidiary of Spruce that will operate as a dedicated endocrinology company (the "Separation

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported financial results for the third quarter ended September 30, 2026, and revised its full-year 2026 net sales and non-GAAP adjusted EBITDA guidance. Unless otherwise noted, pro forma results exclude the impact of the discontinued M6™ product lines. Third Quarter 2026 Highlights Total reported net sales of $207.9 million, representing an increase of 1% on a reported b

NEW YORK & PALO ALTO, Calif.--(BUSINESS WIRE)--TriGemX Bio, Inc. (“TriGemX Bio”), a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for migraine, and TCGX Acquisition Corp. (Nasdaq: TCGX) (“TCGX”), a publicly listed special purpose acquisition company, today announced that Daniel Lynch has been appointed Chairman of the TriGemX Bio Board of Directors (the “Board”). Mr. Lynch will remain Chairman of the Board following the closing of the previously an

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious skin diseases, today provided corporate updates and reported financial results for the three and nine months ended September 30, 2026. Additional Stage 1/Phase 2a results show encouraging response in the full atopic dermatitis trial population In October 2026, Turn Therapeutics reported additional res

NEW YORK--(BUSINESS WIRE)---- $TGTX--TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the third quarter of 2026, along with recent company developments and provided an update on 2026 financial guidance. Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, “With solid third-quarter performance and a strong fourth quarter anticipated, we are on track to exceed $1 billion in global revenue in 2026, less than four ye

LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the Company completed its submission of a New Drug Application (NDA) to the U.S. FDA for COMP360 psilocybin, its investigational synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD). "People living with treatment-resistant depression have gone too long ex

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced positive results from the final analysis of the primary endpoint in Cohort A of QUILT-2.005 (NCT02138734), a randomized, controlled, registrational trial evaluating intravesical ANKTIVA® (nogapendekin alfa inbakicept-pmln/N-803) in combination with Bacillus Calmette-Guérin (BCG) versus BCG alone in patients with BCG-naïve, high-grade non-muscle invasive bladder cance

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Acquire Frontage's Bioanalysis and DMPK Businesses

SAN DIEGO--(BUSINESS WIRE)-- #Medtech--Vektor Medical, a medical technology company transforming cardiac arrhythmia care, today announced that it has won the 2026 MedTech Innovator Mid-Stage Grand Prize, receiving $200,000 in non-dilutive funding. The award recognizes the company's achievements in developing and commercializing vMap®, its FDA-cleared, non-invasive arrhythmia localization technology.MedTech Innovator, the world's largest accelerator of medical technology companies, selected its 2026 cohort

CAMBRIDGE, England & SAN DIEGO--(BUSINESS WIRE)--Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and Contineum Therapeutics, Inc. (Contineum) (NASDAQ:CTNM), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that Qureight’s Fibr8™ quantitative imaging biomarker is being us

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events:2026 Jefferies Global Healthcare Conference in London – November 16-19, 2026Type: Fireside Chat PresentationDate/Time: November 18, 2026, 11:00 am GMTCiti’s 2026 Global Healthcare Conference – November 30 - December 3, 2026Type: Fireside Chat PresentationDate/Time: December 2, 2026, 2:20 pm ESTPiper Sandler 38th Annual Hea

ORLANDO, Fla.--(BUSINESS WIRE)--The American College of Rheumatology (ACR) and the Lupus Foundation of America (LFA) have honored two rheumatologists at Hospital for Special Surgery (HSS) with prestigious career awards recognizing their transformative contributions to lupus research, education and patient care. The ceremonies took place during the ACR Convergence conference in Orlando, Florida, from November 6 to 11. Mary K. Crow, MD, received the Evelyn V. Hess Award from the LFA, which honors

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced presentations by management at the following upcoming investor conferences:Stifel Healthcare Conference 2026 in New York: Fireside Chat on Wednesday, November 11, 2026, at 4:40 p.m. ET.2026 Jefferies Global Healthcare Conference in London: Presentat

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value healthcare company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience, will participate in fireside chats at the following upcoming investor conferences. Jefferies Global Healthcare Conference in London, UK on Tuesday, November 17; fireside chat at 3:00 pm Greenwich Mean Time 9th Annual Evercore Healt

ENGLEWOOD, N.J.--(BUSINESS WIRE)--Phase 2/3: CD206-targeted glucocorticoid 101-PGC-005 beat dexamethasone (HR 2.31), no added steroid; ACR 2026 poster data; partners sought

ORLANDO, Fla.--(BUSINESS WIRE)--A type of cellular therapy originally developed to treat cancer is showing promise as a potential treatment for people with difficult-to-treat lupus, according to a new study from researchers at Hospital for Special Surgery (HSS). Known as chimeric antigen receptor (CAR) T-cell therapy, the approach is increasingly being investigated for the treatment of systemic lupus erythematosus (SLE). The study, CAR T-Cell Therapy in SLE: A Pooled Analysis, was presented tod

HAYWARD, Calif. & ORLANDO, Fla.--(BUSINESS WIRE)--New Aqtual studies reveal why rheumatoid arthritis patients respond to different therapies, supporting development of its RA treatment-selection test.

JERSEY CITY, N.J.--(BUSINESS WIRE)--Analysis of 16,000+ VA patients switching to HADLIMA from HUMIRA showed a 1.3% switchback rate and generated $132M in estimated savings.

MIAMI & ORLANDO, Fla.--(BUSINESS WIRE)-- #ClinicalAI--The American College of Rheumatology (ACR), the professional organization representing more than 10,600 rheumatology professionals worldwide, and OpenEvidence, the most widely used medical AI platform among U.S. physicians, today announced a collaboration at ACR Convergence 2026 to make ACR’s patient education resources available within OpenEvidence, helping rheumatologists, as well as primary care physicians and other specialists managing rheumatic condi

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of an AI model for tumor and immune biology, announced today that it will present new data demonstrating the application of its biologically grounded AI in non-oncology indications at the American College of Rheumatology (ACR) Convergence 2026. ACR Convergence 2026, the world's premier rheumatology event, will be held November 6–11 at the Orange County Convention Center in Orlando, Florida. BostonGene combines multimodal profiling with biol

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the Stephens Annual Investment Conference and the Piper Sandler 38th Annual Healthcare Conference.

ATLANTA--(BUSINESS WIRE)--CareValidate, the compliance and clinical infrastructure behind some of the fastest-growing telehealth brands in the country, is launching same-day prescription delivery in Houston. Telehealth businesses on the CareValidate platform can now offer eligible patients home delivery within hours instead of waiting days for traditional mail-order fulfillment. The launch starts with eligible compounded GLP-1 medications and the antinausea medication, ondansetron. CareValidate

TAMPA, Fla.--(BUSINESS WIRE)-- #MevionFIT--Mevion Medical Systems, a global leader in compact proton therapy, today announced that BayCare Health System has begun treating patients on the MEVION S250-FIT™ Proton Therapy System in Tampa. BayCare is the first in Florida to deliver proton therapy from a standard LINAC-sized room and the second center in the world to treat patients on the platform. The BayCare Proton Center is a $33 million investment that adds a new treatment vault to the Fred J. Woods Radiati

BOSTON--(BUSINESS WIRE)--Nimbus Therapeutics, LLC (“Nimbus Therapeutics” or “Nimbus”), a computational drug discovery company developing breakthrough small molecule medicines through advanced structure-based design and AI-enabled chemistry, today announced that it will present new preclinical data from its highly selective salt-inducible kinase 2 (SIK2) inhibitor program in rheumatoid arthritis (RA) at ACR Convergence 2026, the annual meeting of the American College of Rheumatology, taking plac

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today reported its financial results for the third quarter and nine months ended September 30, 2026, and provided an update on clinical and operational progress. “This quarter marked a period of meaningful momentum for Summit, highlighted by AstraZeneca’s $2 billion strategic equity investment and the expansion of our network of clinical collaborations with AstraZeneca, Daiichi Sankyo, and several others,” said Robert W. Duggan, Ch

JACKSONVILLE, Fla.--(BUSINESS WIRE)--Redwire Corporation (NYSE:RDW, “Redwire” or the “Company”), a global leader in space and defense technology solutions, today announced results for its third quarter ended September 30, 2026. “Redwire continued to see durable demand across our space and defense tech portfolio during the third quarter as evidenced by our record Backlog1 of $619.7 million, a nearly 75% increase year-over-year, and Book-to-Bill1 increasing to 1.73,” stated Peter Cannito, Chairma

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that it will participate in the UBS Global Healthcare Conference, being held in Palm Beach Gardens, Fla., on Tuesday, November 10, 2026, including a fireside chat at 2:45 p.m. ET.The webcast link will be available on the Company’

BARRANQUILLA, Colombia & MIAMI--(BUSINESS WIRE)--Naturmega is pleased to celebrate the launch of LysOmega®, introduced last week by SourceOne Global Partners at SupplySide Global 2026 in Las Vegas. This innovative formulation is the result of a multi-year collaboration in which Naturmega contributed to the development, manufacturing, and supply of a specialized molecular matrix featuring EPA and DHA bonded to phospholipids rich in lysophosphatidylcholine (LPC), through its proprietary Ruby-O® t

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Polaris Rx announced today that it has been selected by Bristol Myers Squibb to dispense ZENBEXUS™ (iberdomide), the first cereblon E3 ligase modulator (CELMoD) therapy approved by the U.S. Food and Drug Administration (FDA). ZENBEXUS is approved, in combination with daratumumab and hyaluronidase-fihj and dexamethasone, for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodul

MELBOURNE, Fla.--(BUSINESS WIRE)--Sun Nuclear, a Mirion Medical company, announced the global launch of Simon™, a cloud-native, vendor-agnostic command center for linear accelerator (linac) health in radiation oncology. Working alongside SunCHECK® software or independently, Simon brings quality assurance (QA) data from across devices, vendors and sites into one comparable record, giving medical physicists a single view of machine health, from individual linacs to an entire network. By applying s

ALACHUA, Fla.--(BUSINESS WIRE)--Neurotronics, a Nihon Kohden company, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its Sleep Analysis Module (SAM).SAM is a software-only medical device that includes a total sleep time (TST) algorithm. The algorithm analyzes a photoplethysmography (PPG) signal to estimate TST and aid health care professionals in the evaluation of sleep disorders.SAM represents the first FDA-cleared AI/ML-based sleep analysis al

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences: Stifel 2026 Healthcare Conference Fireside Chat Date and Time: Tuesday, November 10, 2026 at 9:20 AM ET Loc

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences:Stifel Healthcare Conference on Tuesday, November 10, 2026, at 8:40 a.m. ET in New York City, NYJefferies Global Healthcare Conference on Wednesday, November

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its participation in the Jefferies Global Healthcare Conference, which is being held November 16-19, 2026 at the Waldorf Hilton and ME Hotel in London, UK. Management will participate in a fireside chat on Monday, November 16th at 11:30 a.m. Greenwich Mean Time (6:30 a.m. Eastern Time). A live audio webcast of the fireside chat will be accessible under the “Events” section of the company’s investor relations website:

POOLER, Ga.--(BUSINESS WIRE)--Porter Logistics, a Georgia third-party logistics (3PL) company with warehouses in Atlanta and Savannah, operates the new Teckrez Distribution Center, which held its grand opening and ribbon cutting on Wednesday, Oct. 28, at Porter's Savannah 3PL warehouse at 195 Nordic Way in Pooler. Teckrez, a Jacksonville-based supplier of hydrocarbon resins and monomers, selected Porter to run the center, which opened in February. The center receives Teckrez's import containers

TAMPA, Fla.--(BUSINESS WIRE)--Catalent, Inc., the leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and healthier lives, has appointed Wetteny Joseph as Group President, Pharma and Consumer Health (PCH), effective today. Joseph will lead Catalent’s PCH segment focusing on oral delivery technologies and manufacturing for small and macro molecules, and advanced delivery of self-care solutions, joining Catalent’s Group Executive Commi

BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, an agentic AI and real-world data (RWD) company advancing oncology drug development, commercialization, and access to precision medicine, today announced a partnership with Global Leadership in Oncology & Wellness (GLOW), a 501(c)(3) non-profit dedicated to bridging the gap between patients, caregivers, and the scientific community. Through the partnership, the organizations will work together to connect patients and caregivers in GLOW’s commu

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that members of its management team will participate in the following investor conferences: Jefferies London Healthcare Conference Date: November 16-19, 2026 Location: London, United Kingdom Ci

ATLANTIC BEACH, Fla.--(BUSINESS WIRE)-- #AI--nPhase, Inc., today announced the closing of a $30 million Series D funding round led by Viking Global Investors to accelerate the company’s AI-native clinical data platform for pharmaceutical sponsors seeking to unlock the full potential of their data and power AI at scale. Viking Global Investors is an investment firm managing more than $54 billion in capital across public and private investments. The financing represents nPhase’s first equity capital ra

HANGZHOU, China & NEWARK, Calif.--(BUSINESS WIRE)--Phase 2b/3 trial results show lingdolinurad significantly outperformed febuxostat in treating chronic gout and hyperuricemia

BEIJING & CLEARWATER, Fla.--(BUSINESS WIRE)--Darwin Biotech (“Darwin”), a clinical-stage company developing treatments for neurological diseases, today announced that data from its randomized, double-blind, placebo-controlled Phase 1 study of ALT001 in amyotrophic lateral sclerosis (ALS), including 12-week results from an ongoing open-label extension (OLE), were presented in a poster at the 2026 Network of Excellence for ALS (NEALS) Annual Meeting, taking place October 27-30 in Clearwater, Flor

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the company will report financial results for the third quarter of 2026 on Thursday, November 12, 2026. Management will hold a conference call beginning at 4:30 pm Eastern time to review the results, provide a business update and answer questions.Participants are en

MIAMI & NEW YORK--(BUSINESS WIRE)-- #ClinicalAI--NYU Langone Health, one of the nation’s premier academic health systems and ranked No.1 in the nation for quality by Vizient, Inc., and OpenEvidence, the most popular AI for doctors in the United States, today announced a collaboration to bring OpenEvidence directly into NYU Langone’s Epic electronic health record (EHR), with Patient Aware Clinical Intelligence. Clinicians across NYU Langone will now be able to ask complex clinical questions in natural languag

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- #futuredoctors--Kaplan launches innovative USMLE prep platform featuring personalized learning, adaptive study plans, and tools to help future physicians succeed.

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today reported financial results for the third quarter ended September 30, 2026 and updated its financial guidance for the full year ending 2026. Third Quarter 2026 Highlights(1) Sales of $335.6 million decreased 0.7% year-over-year as reported and decreased 0.8% on a constant currency(2) basis. Excluding the impact of the Company’s previously announced strategic exits of GI product offerings, net sales increased 6.7% on an organic c

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its third-quarter results for the period ended September 30, 2026.

MIAMI & ROCKVILLE, Md.--(BUSINESS WIRE)-- #ClinicalAI--The American Society of Addiction Medicine (ASAM) and OpenEvidence, the most popular AI for doctors in the United States, today announced a collaboration to make ASAM’s clinical guidelines, guidance, and implementation resources accessible through OpenEvidence. This integration enables OpenEvidence’s clinician users to readily access ASAM’s evidence-based guidance for the care of patients with substance use disorders (SUD) and addiction. ASAM’s guidance

NAARDEN, Netherlands & WALTHAM, Mass. & BARCELONA, Spain--(BUSINESS WIRE)-- #ALS--Prilenia Therapeutics B.V. and Ferrerii today announced the presentation of new data and PREVAiLS study updates at the upcoming Northeast Amyotrophic Lateral Sclerosis (NEALS) Consortium 2026 annual meeting in Florida. In a new post hoc analysis of a sub-group of 36 participants with definite or probable ALS (El Escorial Criteria) who are within 18 months from first onset of disease symptoms from the Phase 2 HEALEY Platf

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces a poster presentation at the 2026 Annual NEALS Meeting on October 28th in Clearwater, Florida. NEALS (Network of Excellence for ALS) is the world’s largest ALS research consortium, dedicated to accelerating the development of new treatments for ALS and Motor Neuron Disease (MND). Coya is currently con

SARASOTA, Fla. & AUSTIN, Texas--(BUSINESS WIRE)--Deep Reasoning AI Inc., a company founded by Cornell University artificial intelligence professors, today announced that the U.S. Food and Drug Administration has granted 510(k) clearance (K262134) for NeuroDR, its AI-enabled software for visualizing the arteries of the head and neck from CT angiography (CTA) scans. NeuroDR was developed in collaboration with 3DR Labs, the largest provider of 3D medical image post-processing in the United States,

HOUSTON--(BUSINESS WIRE)--The Walmart Healthcare Research Institute (WHRI) and Care Access, a health and research company, today announced plans to open three additional Clinical Trial Centers in Livonia, Michigan; Las Vegas, Nevada; and San Antonio, Texas in the first half of 2027. The expansion builds on the recent opening of the partnership’s first four centers in Houston and Tyler, Texas; Dalton, Georgia; and Brandon, Florida bringing health screenings and clinical research opportunities int

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following investor conferences: UBS Global Healthcare Conference on Tuesday, November 10, 2026 in Palm Beach Gardens, FL Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum on Wednesday, November 11, 2026 in New York, NY Craig-Hallum A

NEW YORK & BURLINGTON, Mass.--(BUSINESS WIRE)---- $BFLY #POCUS--Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a pioneer and leader in semiconductor-based ultrasound devices, cloud software and AI, today announced that it will attend the UBS Global Healthcare Conference in Palm Beach Garden, FL on November 10, 2026. Joseph DeVivo, President, Chief Executive Officer & Chairman and John Doherty, EVP, Chief Financial Officer, will present and host one-on-one investor meetings. The company presentation wil

MĀHIA, New Zealand--(BUSINESS WIRE)--(MĀHIA SPACEPORT) – SFL Missions Inc. today confirmed the successful deployment of six radio frequency (RF) detection and geolocation satellites for HawkEye 360 of Herndon, Va. SFL Missions delivered the HawkEye 360 Cluster 15 and 16 spacecraft bus units and subsystems with advanced capabilities to HawkEye 360’s facility in Virginia for assembly, integration, and testing under the SFL Flex Production Program. A total of 48 operational HawkEye 360 RF geolocat

HOUSTON--(BUSINESS WIRE)--Voyager Technologies (NYSE: VOYG) executed a mission management contract with Interstellar Lab to host BioPod EDEN, the company’s autonomous plant growth payload, aboard the International Space Station (ISS). “Commercial companies are now delivering research capabilities that governments, space agencies and researchers around the world can put to work on the International Space Station,” said Mattia Pianorsi, managing director, Voyager Technologies Europe. “Our role is

FLORHAM PARK, N.J.--(BUSINESS WIRE)--Shionogi Inc., a New Jersey-based subsidiary of Shionogi & Co., Ltd., (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.), will present three posters at the 2026 Annual Network of Excellence for Amyotrophic Lateral Sclerosis (NEALS) Meeting, taking place October 27-30 in Clearwater, Florida. Shionogi remains committed to advancing ALS research and expanding the understanding of RADICAVA ORS® (edaravone), including through real-wor

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Acelot, a biotechnology company developing small molecule therapies for challenging targets in diseases with high unmet need, today announced that Acelot CMO & CDO Mark Forman, MD, PhD, will present preclinical data from the company’s TDP-43 program at the upcoming 2026 Annual Network of Excellence for ALS (NEALS) meeting, taking place October 27-30 in Clearwater, FL and virtually. Additionally, Acelot CEO Katie Planey, PhD, MBA, will participat

ORLANDO, Fla. & LITTLETON, Mass.--(BUSINESS WIRE)-- #MevionFIT--Adults and children facing cancer will have access to more advanced treatment options close to home as the AdventHealth Cancer Institute introduces proton therapy. The MEVION S250-FIT™ Proton Therapy System will expand the care available to Central Floridians. AdventHealth Cancer Institute brings together cancer specialists, advanced treatments, clinical research and services that support patients’ physical, emotional and spiritual needs. Its n

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III HARMONi-GI1 study evaluating the novel, potential first-in-class investigational bispecific antibody ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy as a first-line treatment for patients with advanced biliary tract cancer (BTC). These data are featured in today’s Presidential Symposium II at the European Society for Medic

MIAMI & SEOUL, South Korea--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) and Lunit Inc. (KRX: 328130) today announced a research agreement to evaluate the use of Lunit SCOPE IO, Lunit’s AI-powered pathology platform, for tumor microenvironment analysis in support of Summit’s immuno-oncology development programs with ivonescimab. The effort will focus on applying Lunit SCOPE IO to hematoxylin and eosin-stained (H&E) whole-slide images to characterize tumor microenvironment featur

WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Medical Manufacturing Technologies (MMT), a leading provider of medical device and industrial manufacturing equipment, automation, and process expertise, today announced the launch of its redesigned website. As the first of its kind in the manufacturing solutions industry, this intuitive digital experience redefines how manufacturers access specialized technical expertise and identify tailored solutions to improve production performance. Reflecting MMT’s

PHILADELPHIA--(BUSINESS WIRE)--Datavault AI Inc. (“Datavault AI” or the “Company”) (Nasdaq: DVLT), an Artificial Intelligence Platform (“AIP”) company providing data monetization, credentialing, and real-world asset (“RWA”) tokenization, today announced that it has entered into a non-binding letter of intent (“LOI”) to acquire a 19.9% equity interest in DataMEDS AI, Inc. (NASDAQ: MEDS) (“DataMEDS”) in consideration of an expansion of its existing technology license with DataMEDS. The proposed t

BOCA RATON, Fla. & SOMERSET, N.J.--(BUSINESS WIRE)-- #AAPS--The acquisition is part of LGM Pharma's strategy to build a U.S.-based analytical services platform alongside its API sourcing business.

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that ivonescimab data will be featured in numerous presentations at the European Society for Medical Oncology 2026 Congress (ESMO 2026), taking place October 23-27, 2026, in Madrid, Spain. Across 10 presentations at ESMO 2026, ivonescimab data will span a broad range of tumor types, led by positive overall survival findings from Akeso Inc.’s Phase III HARMONi-GI1 study of ivonescimab plus chemotherapy compared to du

CONSHOHOCKEN, Pa. & FORT MYERS, Fla.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced it has signed a definitive agreement to acquire American Oncology Network, Inc. (“AON”) (OTCQX: AONC), a physician-led network of more than 350 oncology providers across 21 states. “The acquisition of AON will expand our physician-led oncology MSO and support of care in communities across the country,” said Robert P. Mauch, President and Chief Executive Officer of Cencora. “AON serves as a trusted p

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a clinical trial collaboration with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) to evaluate ivonescimab, a novel, potential first-in-class investigational bispecific antibody, in a registration-enabling Phase II/III study in biliary tract cancer (BTC). The new study, EA2251 (NCT07765433), is designed to evaluate the safety and efficacy of ivonescimab with chemotherapy compared to pembrolizumab or durvalumab pl

ENGLEWOOD, N.J.--(BUSINESS WIRE)--CD206-targeted glucocorticoid 101-PGC-005 beat dexamethasone in 309-patient Phase 2/3 trial (HR 2.31); steroid-sparing data at ACR Poster 0122, Nov 8

TAMPA, Fla.--(BUSINESS WIRE)--Smart Meter, a leader in remote physiologic monitoring (also known as remote patient monitoring or RPM) solutions, today announced two new offerings for qualifying healthcare providers: free patient onboarding and engagement services to improve device use and adherence through its signature SmartTouch® program, and lower monthly service fees. Together, they are designed to help practices start, scale, and sustain RPM programs at a time when administrative demands a

BOCA RATON, Fla.--(BUSINESS WIRE)--Algia Pharma, LLC (“Algia”) today announced the successful completion of its Investigational New Drug (IND)-enabling preclinical toxicology study for AlgiaPak®. AlgiaPak is a hospital-grade multimodal pain regimen designed to treat all mild-to-moderate acute pain as effectively as opioids, without exposing patients to the risk of opioid addiction. Results from the study, conducted in full compliance with Good Laboratory Practice (GLP) standards, demonstrated t

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the initiation and opening of clinical trial sites of a multiregional Phase II study of ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in previously untreated advanced clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer. The study (SMT112-216 / AK112-216 / NCT07877194) is being conducted in collaboration with Summit’s partner, Akeso Inc. SMT

WALTHAM, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a clinical-stage biotechnology company developing novel therapeutics for autoimmunity and cancer, will deliver an oral presentation at the 2026 American College of Rheumatology (ACR) Convergence, taking place November 6-11 in Orlando, Florida. Palleon's presentation will take place on Wednesday, November 11. Details of Palleon's Presentation: American College of Rheumatology (ACR) Convergence Title: Rapid and deep clinical responses to H

MIAMI--(BUSINESS WIRE)-- #COVID19--AIDS Healthcare Foundation (AHF) welcomes the United Nations General Assembly’s adoption of the Political Declaration on Pandemic Prevention, Preparedness, and Response, with 153 countries voting in favor and only three against. AHF urges governments to turn this strong affirmation of international cooperation into concrete commitments that protect people from future pandemics. “Effective coordination on pandemic prevention, preparedness, and response is of utmost import

NEW YORK--(BUSINESS WIRE)--Fortell today announced it is expanding access to its prescription AI hearing aids across more than 30 states through new clinics and Fortell Anywhere, its remote audiology service.Fortell’s custom AI chips use spatial cues to separate speech from competing sounds in real time, directly on the device, and without a perceptible lag. By isolating voices and reducing background noise before amplification, Fortell helps people follow conversations in restaurants, crowded r

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Reservoir today launched a personal cell preservation service that lets adults preserve their own immune cells through a standard blood draw. Reservoir is available today through partner clinics in San Francisco, Boston, Los Angeles, and New York City, with in-home appointments launching in select markets. Sign up at withreservoir.com to be matched with a nearby appointment or to receive updates when Reservoir comes to your city. To see Reservoir in action, go

LAS VEGAS & PANAMA CITY--(BUSINESS WIRE)-- #AABB--Auragens, an international regenerative medicine and research institute, today announced that its research paper, "Molecular Dynamics Simulation of SOD3 and CXCR4 Proteins in Engineered Mesenchymal Stem Cells for Radiation Countermeasure Therapeutics," has been formally accepted for presentation at the 2027 American Institute of Aeronautics and Astronautics (AIAA) SciTech Forum, taking place January 11–15, 2027, in Orlando, Florida.The paper, authored by

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics expanded its partnership with Indica Labs to scale AI-powered digital pathology and support more timely, consistent diagnostic insights.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its third quarter 2026 financial results after the close of the U.S. financial markets on Wednesday, October 28, 2026.

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced a partnership with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida. The partnership covers both the commercial use of the nPulse™ Vybrance™ Percutaneous Electrode System in the treatment of patients at the center and a clinical collaboration to

MIAMI & BALTIMORE--(BUSINESS WIRE)-- #ClinicalAI--OpenEvidence and Johns Hopkins Medicine are collaborating to design medical education and clinical care for the AI era, with patients at the center.

WALTHAM, Mass.--(BUSINESS WIRE)-- #ACR2026--Fortitude Biomedicines Announces Oral Presentation of FTB-918 for the Treatment of Axial Spondyloarthritis at ACR Convergence 2026.

NEW CASTLE, Del. & SAN ANTONIO--(BUSINESS WIRE)--IgniteData, a leader in intelligent clinical trial data automation, and RealTime eClinical Solutions, a leader in clinical research software solutions, today announced a new partnership which will provide RealTime’s network of clinical research sites with expanded access to IgniteData’s Archer platform to securely and efficiently transfer clinical data. Archer is the only platform built from the ground up solely to solve for long-standing data tr

WHITMORE LAKE, Mich. & SARASOTA, Fla.--(BUSINESS WIRE)--Trace Medical, a national leader in advanced respiratory rentals and biomedical services, announced that it has acquired a majority interest in LiViliti Health Products, Inc. The acquisition follows LiViliti receiving 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Paptizer 360 classified as a Class II Respiratory Accessory Microbial Reduction Device for CPAP equipment. The majority acquisition builds upon the exi

TAMPA, Fla. & WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Catalent, Inc., the leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and healthier lives, and Mantra™, a consumer health company developing single-serve, over the counter (OTC) oral gel products for everyday relief, today announced a commercial supply agreement for Mantra’s oral gel product platform. Catalent will provide formulation development, commercial manufacturing and pa

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American, Symbol: CCEL) (the “Company”, “Cryo-Cell”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2026. Financial Results Revenue Consolidated revenues for the third quarter of fiscal 2026 were $7.82 million compared to $7.83 million for the third quarter of fiscal 2025. Net Income The Company reported net income of $1.27 mil

STUART, Fla.--(BUSINESS WIRE)--Stuart Therapeutics Inc., a late-stage biopharmaceutical company developing a new class of therapeutics designed to treat eye diseases by repairing helical collagen, today announced it has submitted an investigational new drug application amendment to the U.S. Food and Drug Administration to study its lead candidate, ST-100 (vezocolmitide), in corneal wound healing. The planned proof-of-concept study would mark ST-100's first expansion beyond dry eye disease and co

BOCA RATON, Fla.--(BUSINESS WIRE)-- #LumbarDecompression--SurGenTec®, a privately held medical device company focused on advancing treatment options for orthopedic and spine surgery, today announced that it has entered into an exclusive license agreement with Allevion Medical for its patented Vantage™ spinal decompression technology. Under the terms of the agreement, SurGenTec® has secured exclusive rights to Allevion Medical's Vantage™, a fully disposable, sterile system designed to simplify and enhance minimally in

DENVER--(BUSINESS WIRE)-- #AI--Cleerly, a leader in advanced cardiovascular imaging analysis, and Clear Heart and Lung Imaging, a leader in outpatient imaging care, have taken a cardiac-capable mobile CT scanner across the southern United States to expand access to cardiovascular research and enable communities and clinics to participate in Cleerly's TRANSFORM Trial. From July through September 2026, the CT scanner traveled through Arizona, Louisiana, Georgia, and Florida, bringing cardiovascular ima

KENNEDY SPACE CENTER, Fla.--(BUSINESS WIRE)--Starfighters Space, Inc. ("Starfighters" or the "Company") (NYSE American: FJET), the space company operating the world's only commercial fleet of flight-ready Mach 2+ supersonic aircraft, today announced the completion of its first flight hardware manufactured under a production agreement with Italian engineering company Robby Moto Engineering S.R.L. ("RME"), marking an important milestone in the Company's continued development of its previously ann

LAUSANNE, Switzerland, WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Timeline (Amazentis SA), the Swiss life-sciences company that pioneered the healthy aging ingredient Urolithin A and its branded form Mitopure®, together with its U.S. subsidiary Timeline Longevity, Inc., announced today that the U.S. District Court for the District of Massachusetts has granted an ex parte temporary restraining order against the operators of a network of websites that impersonate Timeline’s official site, www.timeli

LAKELAND, Fla.--(BUSINESS WIRE)--As Publix celebrates National Seafood Month, the company continues its long-standing commitment to advancing sustainable seafood by donating nearly $100,000 to Sustainable Fisheries Partnership (SFP) in 2026 alone, bringing its total contribution to the organization to more than $1.2 million.Now in its 16th year, Publix’s collaboration with the nonprofit highlights the company’s environmental stewardship and responsible sourcing efforts. SFP works with the seafoo

MIAMI LAKES, Fla.--(BUSINESS WIRE)-- #Cordis--Cordis, a global leader in interventional cardiovascular and endovascular technologies, today announced that the SELUTION SLR SUSTANE™ PTA Drug-Eluting Balloon (SUSTANE DEB) achieved the highest reported 12-month primary patency in the SELUTION4SFA US pivotal trial at 90.3%. The results were presented during a Late-Breaking Clinical Trial session at VIVA 2026 by Jay Mathews, MD, MS, Director, Cardiac Catheterization Laboratory, PERT & Structural Heart at

MIAMI--(BUSINESS WIRE)--DemeRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming addiction therapeutics, today announced the appointment of Juan R. Sanchez-Ramos, M.D., Ph.D., to its Scientific Advisory Board. A neurologist and clinician-scientist whose career has spanned addiction, movement disorders, and neurodegenerative diseases, Dr. Sanchez-Ramos was an early leader in the clinical investigation of ibogaine and a scientific collaborator of DemeRx founder and CEO D

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics today announced its executive leadership and board of directors succession plan.

MELBOURNE, Fla.--(BUSINESS WIRE)--Smart seating company Kalogon names former Meta, Magic Leap executive Marty Evans as its first chief technology officer.

TAMPA, Fla.--(BUSINESS WIRE)--Catalent, Inc., the leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and healthier lives, today announced the U.S. launch of an accelerated gene-to-drug substance program for complex biologics, designed to help developers move bispecifics, multispecifics and other next-generation molecules from gene sequence to drug substance in 10 months. The program builds on Catalent's Rapid Antibody offering for t

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closing of AstraZeneca’s (LSE/STO/NYSE: AZN) strategic equity investment in Summit. The equity investment will support continued acceleration of the development of ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody. Pursuant to the terms of the Securities Purchase Agreement entered into by Summit and AstraZeneca, AstraZeneca purchased an aggregate of approxi

ANTALYA, Turkey & JACKSONVILLE, Fla.--(BUSINESS WIRE)---- $RDW--Redwire Corporation (NYSE: RDW), a global leader in space and defense technology solutions, today announced it has been awarded a contract by Axiom Space, a leader in next-generation space infrastructure, to develop and deliver two Roll-Out Solar Array (ROSA) wings for Axiom Station’s second space station module. As previously announced, Redwire is also building the ROSA wings for Axiom Space’s first space station module. “We are excited an

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robu

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced a clinical trial collaboration agreement with Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) to evaluate ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in combination with Datroway® (datopotamab deruxtecan), a TROP2-directed antibody drug conjugate (ADC), across multiple solid tumor settings, intending to include breast and lung cancer. The companies i

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the third quarter 2026 after the market close on Wednesday, October 28, 2026. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via live webcast, please click here. To participate via telephone, please click here to pre-register and obtain the dial-in number and passcode. This confer

ORLANDO, Fla.--(BUSINESS WIRE)-- #MedicalDevices--Xenix Medical Announces FDA Clearance of NanoACTIV™ Surface Technology for Its Riva® Posterior Fixation System.

BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, Inc., an agentic AI and real-world data company advancing oncology drug development and access, today announced its inclusion in TIME’s World’s Top HealthTech Companies 2026 in the AI & Data Analytics category. Produced in collaboration with Statista, the list recognizes 500 companies worldwide based on financial performance, reputation and online engagement. The recognition comes as Massive Bio expands its role as oncology data and AI infrast

CORAL SPRINGS, Fla.--(BUSINESS WIRE)--ACIC Equipment USA will join ACIC Pharmaceuticals at CPHI Milan 2026, bringing together ACIC's pharmaceutical expertise and global network of technology partners to showcase an integrated approach to pharmaceutical development, manufacturing and commercialization. From October 6–8, 2026, visitors to Stand 7G106 can meet both teams and discover how ACIC connects pharmaceutical expertise, advanced manufacturing technologies and specialized engineering to help

BOCA RATON, Fla. & COLUMBUS, Ohio--(BUSINESS WIRE)--The TECPR2 Research Foundation, a nonprofit organization established to advance research and development of a treatment for patients with TECPR2, and Forge Biologics (“Forge”), a leading manufacturer of gene therapies and member of Ajinomoto Bio-Pharma Services, today announced a development and manufacturing partnership to advance an AAV gene therapy for patients with TECPR2, an ultra-rare neurodegenerative genetic disease. Under the partners

GAINESVILLE, Fla.--(BUSINESS WIRE)--Neuropacs™ Corp. today announced that its Co-Founder & Chief Scientific Officer, Dr. David Vaillancourt, will serve as a key scientific leader in a $22 million National Institutes of Health grant supporting the University of Florida-led Alzheimer’s Disease Research Center (1Florida ADRC). The award positions Florida among a select national network of only 37 ADRCs in the United States and the only one located in the state, expanding the region's role in a

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced key developments important to the company’s progress towards achieving its goal of making a significant difference in the lives of patients with cancer. Specifically, Summit has established agreements with AstraZeneca (LSE/STO/NYSE: AZN) for a strategic equity investment in Summit and a clinical collaboration focused on ivonescimab and sonesitatug vedotin (sone-ve). Moreover, Summit and AstraZeneca intend to evaluat

MIAMI & NUREMBERG, Germany--(BUSINESS WIRE)--DermaSensor Inc., a leader in AI-powered skin cancer risk detection technology, today announced the commercial launch of DermaSensor in Germany through a distribution agreement with ContraCare GmbH. The launch represents a significant milestone in DermaSensor’s international expansion following its recent Class IIb CE Mark under the European Union Medical Device Regulation (MDR) and collaboration with the National Health Service (NHS) in the United K

MELBOURNE, Fla.--(BUSINESS WIRE)--Sun Nuclear, a Mirion Medical company, today announced that its AdaptCHECK™ software has been validated in collaboration with Siemens Healthineers technical experts and clinical partners for interoperability with the company's new radiotherapy system, Accela. Unveiled at the annual ASTRO conference, Accela is the first software-driven delivery system engineered for NeoArc (Dynamic Modulated Arc Therapy, DMAT), a new treatment technique that accelerates how radia

MIAMI-DADE, Fla. & BROWARD, Fla. & PALM BEACH, Fla. & DUVAL, Fla. & HILLSBOROUGH, Fla.--(BUSINESS WIRE)--Little more than half (52%) of respondents, and less than half (43%) of those aged 30-39, are very aware that breast cancer diagnoses have been rising among younger patients, according to a poll of more than 1,000 Florida-based women. Findings show 32% are somewhat aware of this increase, and 17% are either not very aware (11%) or not at all aware (6%). Conducted by the TopLine MD Alliance —

MELBOURNE, Fla.--(BUSINESS WIRE)--Sun Nuclear, a Mirion Medical company, will bring next-generation innovations for next-level confidence to the ASTRO 2026 Annual Meeting, beginning Sunday, September 27, in Boston. At Booth 915, attendees will get a first look at new solutions for radiation therapy quality assurance (QA), alongside dedicated programming on smarter QA workflows and one of oncology's fastest-growing areas: radiopharmaceutical therapy.An Exclusive Look: A New Way to See Machine Hea

EDISON, N.J.--(BUSINESS WIRE)-- #CollaborativeSurgicalIntelligence--Redefine Surgery, a medical technology company building physical AI for surgery, today announced the closing of an oversubscribed pre-seed financing round, bringing total capital raised to $10 million. Backed predominantly by surgeon investors, the financing will support continued development of the company’s surgical intelligence platform as it advances toward commercialization. The financing announcement follows Wednesday’s announcement by Catalyst OrthoScience

MIAMI & COLLEGE PARK, Md.--(BUSINESS WIRE)--IonQ (NYSE: IONQ), the world’s leading full-stack quantum platform and foundry, today announced a contract with Florida International University (FIU), Miami’s top ranked state university. Under the agreement, IonQ will deliver its Superion 256-qubit trapped-ion quantum computer for installation at FIU.This contract establishes FIU as IonQ’s flagship academic partner in Florida, creating a central hub for quantum research and education across the regio

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Together with more than 20,000 Associates nationwide, AutoNation, Inc. (NYSE:AN) celebrates a decade of DRV PNK and more than $50 million raised and donated to drive out cancer. To commemorate these milestones, AutoNation announced an additional $1 million investment through 10 grants of $100,000 each to 10 longtime partners advancing cancer research and supporting patients, survivors, and caregivers. Over the past decade, DRV PNK has evolved into a defin

NAPLES, Fla.--(BUSINESS WIRE)--Catalyst OrthoScience, Inc. ("Catalyst"), a private medical technology company elevating shoulder arthroplasty through surgeon-focused innovation, today announced it has become the founding partner for shoulder with Redefine Surgery. Building on Catalyst’s leadership in efficient, outcomes-focused shoulder replacement, the partnership expands Catalyst’s role in shaping how shoulder replacement is measured, optimized and continuously improved, unlocking new levels

TAMPA, Fla. & SAN FRANCISCO--(BUSINESS WIRE)--ApalyRx, the pharmacy technology platform that assesses every prescription in real time and routes it to its lowest-cost fulfillment channel on benefit, today announced a partnership with Vida Health, a leading digital health company delivering integrated, longitudinal cardiometabolic and behavioral health care. Together, ApalyRx and Vida Health are enabling self-funded employers to provide plan members with comprehensive clinical weight-loss care a

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Polaris Rx, a leading provider of long-term care, specialty, and infusion pharmacy solutions, has once again been selected as the exclusive U.S. distributor for FluMist® Home, AstraZeneca's at-home flu vaccine service, available for the 2026-2027 flu season. This marks the second consecutive year Polaris Rx has earned this exclusive distinction. Through FluMist Home, individuals can order FluMist online to be delivered directly to their home without a doc

CORAL SPRINGS, Fla.--(BUSINESS WIRE)--ACIC Equipment USA Inc. is pleased to announce the appointment of Patrice Pelletier as President. In this role, Patrice will lead ACIC Equipment's sales strategy and commercial execution across North America, while also driving the strategic development of a new US facility for the company. Patrice brings more than 20 years of executive leadership experience across industrial technology, infrastructure, and energy transition, with a track record of scaling

ORLANDO, Fla.--(BUSINESS WIRE)-- #InterbodyFusion--Xenix Medical Announces FDA Clearance of the Riva® Anchor Spinopelvic Fixation System with NanoACTIV™ Surface Technology

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that data from the Phase III HARMONi-GI1 trial, conducted in China and sponsored by Akeso, Inc., featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab, will be featured as part of the Presidential Symposium II at the European Society for Medical Oncology 2026 Congress (ESMO 2026) which takes place October 23–27, 2026, in Madrid, Spain. The presentation will take place on Sunday, O

MIAMI LAKES, Fla.--(BUSINESS WIRE)-- #Cordis--Cordis, a global leader in interventional cardiovascular and endovascular technologies, today announced that the U.S. Food and Drug Administration (FDA) has approved the SELUTION SLR™ (Sustained Limus Release) Drug-Eluting Balloon (DEB) for the treatment of coronary in-stent restenosis (ISR), marking a major milestone in expanding treatment options for one of the most complex challenges in interventional cardiology. Physicians now have immediate access to the

BOCA RATON, Fla.--(BUSINESS WIRE)--US healthtech company Massive Bio has appointed international business development consultancy Intralink to support its expansion into South Korea and build partnerships across the country's oncology sector. Massive Bio provides an AI-powered platform that connects cancer patients with suitable clinical trials. The company works with global pharmaceutical companies, hospitals and oncologists to identify patients who meet the often highly specific requirements

MIAMI & PHILADELPHIA--(BUSINESS WIRE)--OpenEvidence, the most widely used medical AI and clinical decision-making tool among U.S. physicians, and Penn Medicine today announced a global partnership to bring AI-powered clinical decision support to Penn Medicine's more than 10,000 clinicians across its seven-hospital U.S. health system. That clinical decision support will also extend to low and middle income countries through the Botswana-UPenn Partnership (BUP). Building on Penn Medicine’s deep c

AGOURA HILLS, Calif.--(BUSINESS WIRE)-- #A2B395--A2 Biotherapeutics to Announce Findings from DENALI-1 Study of A2B395 at 2026 Cell Coast Conference

STUART, Fla.--(BUSINESS WIRE)--Stuart Therapeutics, Inc. (“Stuart”), a late-stage biopharmaceutical company developing a new class of therapeutics designed to repair helical collagen for the treatment of eye diseases, today announced that Eric Schlumpf, President and CEO of Stuart Therapeutics, will participate in a fireside chat discussion at the Citizens Private Ophthalmology Summit on Thursday, September 17, 2026, at 2 p.m. EDT. The Summit will showcase innovation in ophthalmology with prese

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) announced that updated overall survival (OS) results from the global Phase III HARMONi clinical trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab were presented today at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC 2026) in Seoul, Republic of Korea. As Summit previously announced on July 22, 2026, ivonescimab plus plat

FERNANDINA BEACH, Fla.--(BUSINESS WIRE)-- #KnowLpa--The Family Heart Foundation, a leading research, education and advocacy organization, today announced the publication of a new peer-reviewed study in JACC: Advances demonstrating how its FIND Lp(a)® Machine Learning Model can identify people with atherosclerotic cardiovascular disease (ASCVD) who are more likely to have high lipoprotein(a) — or Lp(a). The model has already been successfully deployed at five large U.S. healthcare systems participating in

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Perdoceo Education Corporation Signs Definitive Agreement to Acquire South University

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced that updated data, including overall survival (OS), from the randomized, double-blind Phase III HARMONi-2 trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab is being presented at the International Association for the Study of Lung Cancer’s (IASLC) 2026 World Conference on Lung Cancer (WCLC 2026) in Seoul, Republic of Korea. The HARMON

MIAMI & OTTAWA, Ontario--(BUSINESS WIRE)-- #Canada--OpenEvidence and the Medical Identification Number for Canada Corporation (MINC#NIMC) today announced a partnership to streamline physician verification for Canada and support continued free access for verified Canadian clinicians. Medical knowledge keeps accelerating, and clinicians do not have time to chase down answers across dozens of tabs and paywalls. This partnership reduces friction at the moment of sign-up by allowing Canadian physicians to ver

SARASOTA, Fla.--(BUSINESS WIRE)--Belenos Biosciences, Inc. (“Belenos”), a clinical-stage biotechnology company developing long-acting bispecific antibodies for chronic inflammatory diseases, today announced positive interim results from its ongoing randomized, double-blind, placebo-controlled Phase 1b study of BEL512, an investigational long-acting bispecific antibody targeting thymic stromal lymphopoietin (“TSLP”) and interleukin-13 (“IL-13”), in patients with mild-moderate asthma. Phase 1b Tr

BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, Inc., a global leader in AI-driven precision oncology and clinical trial matching, and PrecisCa, an oncology practice support platform offering evidence-based treatment guidance, clinical trial matching, patient communications, and expert second opinions, today announced a strategic partnership to expand cancer patient access to clinical trials across the United States. Under the agreement, Massive Bio will provide concierge support, reporting, an

NAPLES, Fla.--(BUSINESS WIRE)--Catalyst OrthoScience Inc. (“Catalyst”), a private medical device technology company redefining shoulder arthroplasty through simplified, surgeon-focused innovation, today announced that it has entered into a settlement agreement with Shoulder Innovations, Inc. (“Shoulder Innovations”) to resolve all pending patent litigation between the two companies. The agreement resolves the dispute in its entirety. The terms of the settlement agreement are confidential. “Inte

KENNEDY SPACE CENTER, Fla.--(BUSINESS WIRE)--Starfighters Space, Inc. (“Starfighters” or the “Company”) (NYSE American: FJET), the space company operating the world’s only commercial fleet of flight-ready Mach 2+ supersonic aircraft, and Vaya Defense & Space, Inc. (“Vaya”), a privately held developer of the patented Vortex-Hybrid rocket engine, today announced entering into a memorandum of understanding (MOU) to explore collaboration on supersonic captive-carry flight testing and air-launch

MIAMI--(BUSINESS WIRE)--Lotus Neuro, a clinical-stage biotechnology company pairing focused ultrasound with leading therapeutic modalities to treat focal neurologic disease, today announced its public launch. Spun out in December 2025 from Insightec, the global leader in incisionless focused ultrasound, Lotus Neuro is built on a clinically validated platform for precision modulation of the blood-brain barrier (BBB) and is dedicated to solving the delivery problem that has stalled decades of pro

MIAMI--(BUSINESS WIRE)--DermaSensor Inc., a leader in AI-powered skin cancer diagnostic technology, announced today the close of a $4M Series B extension, including institutional and strategic investors, alongside the launch of a community investment round on Wefunder. This new community financing has already raised more than $1 million at the same terms as the $4M. This follows the company’s $16M Series B, closed in 2025, and brings the total investment in the company to $48 million. The commu

MIAMI--(BUSINESS WIRE)-- #Glaucoma--Heru announced the U.S. launch of the new PretestPro on its Heru Prime wearable platform. PretestPro runs four pretest exams in just 90 seconds.

ATLANTIC BEACH, Fla.--(BUSINESS WIRE)--nPhase launches nPhase.ai and its agentic SCE, turning raw clinical trial data into submission-ready CDISC outputs 4x faster with 80% fewer resources.

LAKE FOREST, Calif.--(BUSINESS WIRE)--SinglePass, Inc., developer of the SinglePass biopsy closure device, today announced the publication of a multicenter (Hoag Health System, Newport Beach and Irvine, California) retrospective clinical data study in the Journal of Vascular and Interventional Radiology (JVIR). Across 120 consecutive patients followed for 30 days, the SinglePass device achieved a 100% technical success rate with zero clinically significant bleeding events.1 Percutaneous biopsy

MONTPELLIER, France & MIAMI--(BUSINESS WIRE)--Precision IO Group, the parent company of NeuWave Medical and Quantum Surgical, will unveil new features for its Epione® robotic platform at the 2026 annual congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) in Copenhagen, Denmark, September 5–9, on Booth D39. The updated platform will feature new AI capabilities and compatibility with one of the latest-generation angiography systems from GE HealthCare enabling

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced positive overall survival (OS) results from the randomized, double-blind Phase III HARMONi-2 study evaluating ivonescimab monotherapy against pembrolizumab monotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expression. HARMONi-2 (AK112-303) is a single-region, multi-center Phase III study conducted in China

MIAMI--(BUSINESS WIRE)--Over 90 Segal Trials employees have joined CISCRP’s 8th Annual Medical Heroes Appreci-A-Thon, a two-week event combining physical activity and fundraising to recognize the clinical research participants and professionals who make medical progress possible. Running September 1 through September 15, the Appreci-A-Thon raises funds to support CISCRP’s work educating and empowering patients and the public about clinical research. Just two days into the challenge, Segal Trial

KENNEDY SPACE CENTER, Fla.--(BUSINESS WIRE)--Starfighters Space, Inc. ("Starfighters" or the "Company") (NYSE American: FJET), the space company operating the world's only commercial fleet of flight-ready Mach 2+ supersonic aircraft, today announced it has signed a memorandum of understanding (“MOU”) with The Bionetics Corporation (“Bionetics”) to integrate and process a series of pathfinder small payloads for missions aboard the Company’s F-104 aircraft. Under the MOU, Bionetics will work with

MIAMI--(BUSINESS WIRE)-- #DebtJustice--AIDS Healthcare Foundation (AHF), in collaboration with the University of Miami Public Health Policy Lab, will co-host a webinar, “Freedom from Debt: A Global Dialogue on Fiscal Space, Health, and Development,” on Thursday, September 3, 2026, at 10:00 AM EDT, virtually via Zoom. Register here. Sovereign debt has emerged as a defining challenge at the intersection of global finance, sustainable development, and public health. Across many low- and middle-income countries,

KENNEDY SPACE CENTER, Fla.--(BUSINESS WIRE)--Starfighters Space, Inc. ("Starfighters" or the "Company") (NYSE American: FJET), the space company operating the world's only commercial fleet of flight-ready Mach 2+ F-104 supersonic aircraft, announced it will participate in the September 12-13 AIRSHO at the Midland International Air & Space Port in Texas, showcasing its historic F-104 aircraft in both flight and static displays. For Starfighters, the event provides a unique opportunity to sho

MIAMI--(BUSINESS WIRE)--DermaSensor Inc., a leader in AI-powered skin cancer diagnostic technology, today announced a major expansion of its U.S. commercial strategy through a series of strategic partnerships to accelerate adoption of its FDA cleared, handheld skin cancer detection device across primary care, enterprise healthcare, and federal healthcare systems. The Company's commercial expansion includes 1) an approved supplier relationship with Henry Schein, Inc., the world’s largest provide

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the Morgan Stanley 24th Annual Global Healthcare Conference, Sept. 14–16, 2026, in New York.

MIAMI & LEAWOOD, Kan.--(BUSINESS WIRE)-- #clinicalai--The American Medical Society for Sports Medicine (AMSSM) and OpenEvidence today announced a partnership that will focus on co-developing AI-powered educational resources on sports medicine for both patients and clinicians. This exclusive collaboration brings the expertise of AMSSM’s sports medicine physicians to OpenEvidence, the leading AI-powered clinical decision support platform, and will build on the AMSSM’s robust foundation of educational materials.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced expanded MolDX coverage for its RaDaR® ST MRD assay for immunotherapy monitoring in late-stage solid tumors.

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its participation in the Wells Fargo 21st Annual Healthcare Conference, which is being held September 8-10, 2026 at the Encore Boston Harbor in Everett, MA. Management will participate in a fireside chat on Wednesday, September 9th at 1:30 p.m. Eastern Time. A live audio webcast of the fireside chat will be accessible under the “Events” section of the company’s investor relations website: https://www.conmed.com/en/inv

STUART, Fla.--(BUSINESS WIRE)--Stuart Therapeutics, Inc. (“Stuart”), a late-stage biopharmaceutical company developing first-in-class collagen-reparative therapeutics to treat eye diseases, today announced the appointment of Dave LeCause as senior commercial advisor. LeCause will lead the company's commercial strategy as Stuart advances its lead therapeutic candidate, ST-100 for dry eye disease. ST-100 is expected to begin Phase 3b clinical trials in the first quarter of 2027. LeCause joins Stu

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced positive topline results from the randomized Phase III HARMONi-GI1 study (AK112-309) evaluating ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy as a first-line treatment for patients with advanced biliary tract cancer (BTC). HARMONi-GI1 is a single-region, multi-center, Phase III study conducted in China and sponsored by Akeso, with all relevant data exclusi

TAMPA, Fla.--(BUSINESS WIRE)--Catalent has completed a significant debt refinancing transaction to support its future growth while reducing its annual interest expenses.

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the publication of primary analysis results from the global Phase III HARMONi clinical trial in The Lancet Oncology. In HARMONi, ivonescimab in combination with platinum-doublet chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to placebo plus platinum-doublet chemotherapy in patients with epidermal growth factor receptor (EGFR)-mu

MIAMI LAKES, Fla.--(BUSINESS WIRE)-- #ClinicalResearch--Segal Trials today announced its participation in the Phase 2 ZEPHYR clinical trial evaluating MapLight Therapeutics’ investigational muscarinic receptor-targeted therapy, ML-007C-MA, for the treatment of adults experiencing an acute exacerbation of schizophrenia.MapLight Therapeutics recently announced topline results from the multicenter Phase 2 study. Segal Trials is proud to have contributed to this important clinical development program and congratulates

MIAMI--(BUSINESS WIRE)-- #AI--Arcadia Capital, the premier strategic advisor and investment bank to leaders in the tech and tech services ecosystem, served as exclusive financial advisor to InformedDNA ("IDNA" or "the Company"), a portfolio company of Truehelm and QHP Capital, in the divestiture of its Genetic Testing Utilization Management ("GTUM") business unit to Zyter, a subsidiary of Infinite, a global technology company. The transaction marks the Company's continued investment in and focus on D

TAMPA, Fla.--(BUSINESS WIRE)--Smart Meter, a leading provider of cellular-connected remote patient monitoring (RPM) solutions, today called on RPM vendors, healthcare providers, and industry partners to mobilize against provisions in the Centers for Medicare & Medicaid Services' (CMS) proposed Calendar Year 2027 Physician Fee Schedule (PFS) that could sharply curtail access to remote monitoring for millions of Medicare beneficiaries. The proposed rule, issued July 14, 2026, includes several

MINNETONKA, Minn. & REHOVOT, Israel & ORLANDO, Fla.--(BUSINESS WIRE)--Stratasys Ltd. (NASDAQ: SSYS), a global leader in additive manufacturing solutions, and Limbitless Solutions, a nonprofit research facility at the University of Central Florida dedicated to empowering children through bionics, today announced the expansion of a 12-year collaboration that has already helped deliver hundreds of 3D-printed prosthetic devices to children across the United States and beyond. The expanded partnersh

STUART, Fla.--(BUSINESS WIRE)--Stuart Therapeutics, Inc. (“Stuart”), a clinical-stage biopharmaceutical company developing first-in-class collagen-reparative therapeutics to treat eye diseases, today announced the appointment of David Jakeman as chief financial officer. Jakeman will lead the company's finance and accounting operations as Stuart advances its lead candidate, ST-100 for dry eye disease, through completion of its pending Phase 3b clinical trial and into preparations for commerciali

PALM BEACH GARDENS, Fla.--(BUSINESS WIRE)--Wellvii today announced that its innovative BP Go blood pressure monitoring technology achieved FDA clearance, marking a significant milestone in the company’s mission to transform remote patient monitoring and connected healthcare. The BP Go is designed to simplify the blood pressure measurement by utilizing a convenient finger-based measurement approach, eliminating many of the challenges associated with traditional arm cuffs. The device is designed

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended June 30, 2026. Highlights included: Revenues of $2.3 million for the quarter ended June 30, 2026, a decrease of $5.0 million, from the 2025 quarter. The decrease was driven by a lower number of un

BOCA RATON, Fla.--(BUSINESS WIRE)-- #HealthcareInnovation--SurGenTec®, a developer of surgical technologies for spine and orthopedic procedures, today announced that it has been named to the 2026 Inc. 5000, the annual list of the fastest-growing private companies in America. The prestigious list recognizes companies that have achieved remarkable growth while driving innovation, creating jobs, and shaping the future of the economy. Companies on the 2026 Inc. 5000 are ranked according to percentage revenue growth from 2

HOLLYWOOD, Fla. & DALLAS--(BUSINESS WIRE)--DermCare Management, LLC (“DermCare”), a leader in specialized dermatology and cosmetic surgery practice-management services, and U.S. Dermatology Partners (“USDP”), a leading dermatology practice, today announced the completion of a strategic transaction that creates one of the largest dermatology groups in the U.S., spanning 12 states. The transaction unites two clinically focused organizations with aligned missions to expand access to high-quality d

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that, on August 12, 2026, its partner Akeso Inc. (Akeso, HKEX Code: 9926.HK) announced receipt of marketing authorization in China from the National Medical Products Administration (NMPA) for the use of ivonescimab, a novel, potential first-in-class investigational bispecific antibody, in combination with chemotherapy for the first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC). Thi